secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001628280-22-021955
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Therapeutics loses Head of Development; internal replacement named
--------------------------------------------------------------------------

- Rob Schott, M.D., SVP Head of Development, resigns effective August 19, 2022 to pursue new opportunity.
- Resignation not due to any disagreement with the Company on operations, financial statements, or policies.
- Nathalie Dubois-Stringfellow, Ph.D., currently SVP Product Development, will succeed as SVP Head of Development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828022021955/0001628280-22-021955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828022021955/sgmo-20220808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-021955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer